CytoDyn (OTCMKTS:CYDY – Get Free Report) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.04, Zacks reports.
CytoDyn Stock Performance
Shares of CytoDyn stock traded up $0.00 on Wednesday, reaching $0.20. The company had a trading volume of 117,800 shares, compared to its average volume of 1,753,920. CytoDyn has a 52-week low of $0.18 and a 52-week high of $0.40. The firm has a market cap of $303.55 million, a PE ratio of -9.99 and a beta of 1.50. The firm’s 50 day moving average price is $0.21 and its two-hundred day moving average price is $0.25.
CytoDyn Company Profile
CytoDyn Inc is a biotechnology company focused on the development of leronlimab, an investigational monoclonal antibody that targets CCR5, a receptor involved in immune-cell signaling and the movement of certain cells through the body. The company’s research has explored potential applications in infectious diseases, oncology and inflammatory conditions.
Leronlimab, also known as PRO 140, has been studied primarily as a potential treatment for HIV infection, including in combination with existing antiretroviral therapies.
Read More
- Five stocks we like better than CytoDyn
- High Voltage Returns: Navitas Rewires AI Data Centers
- Quantum BioPharma’s Phase 2 Shows Where Biotech Value Actually Gets Built
- Albertsons Is Betting on a Turnaround—But Will It Pay Off?
- Venezuela’s Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
